Clinical trial
Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety…
NCT00445913 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00445913 |
|---|---|
| Title | Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study |
| Official title | Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study |
| Lead sponsor | University of Pittsburgh, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Type 1 Diabetes |
| Intervention type | Biological |
| Interventions | Diabetes-suppressive dendritic cell vaccine, control dendritic cells |
| Enrollment | 10 |
| Start date | Mar 1, 2007 |
| Primary completion | Jan 1, 2012 |
| Completion | Feb 1, 2016 |
| First posted | Mar 9, 2007 |
| Last update posted | Feb 15, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: